SARS-CoV-2 antibody status at time of delivery and the risk of preeclampsia.

Caparo Farfán, Carlos Alberto; Webb Camminati, Camille María; Portmann Baracco, Arianna Sibila; Nuñez Mochizaki, Claudia; Trelles Yenque, Juan Gualberto; La Rosa de los Rios, Mauricio Francisco; Alcorta Proaño, Rodrigo Gerónimo

dc.contributor.author	Portmann Baracco, Arianna Sibila
dc.contributor.author	Alcorta Proaño, Rodrigo Gerónimo
dc.contributor.author	Nuñez Mochizaki, Claudia
dc.contributor.author	Webb Camminati, Camille María
dc.contributor.author	Trelles Yenque, Juan Gualberto
dc.contributor.author	Caparo Farfán, Carlos Alberto
dc.contributor.author	La Rosa de los Rios, Mauricio Francisco
dc.date.accessioned	2023-06-12T16:25:54Z
dc.date.available	2023-06-12T16:25:54Z
dc.date.issued	2023
dc.identifier.uri	https://hdl.handle.net/20.500.12866/13602
dc.description.abstract	OBJECTIVE: Evaluate the association between SARS-CoV-2 serologic status in immunologically naïve patients and risk of preeclampsia at time of delivery. STUDY DESIGN: We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1st to September 30th, 2020. We recorded maternal medical and obstetric characteristics, and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed and patients were classified into seropositive groups: IgG+, IgM+, or both IgG+ and IgM+. Bivariate and multivariable analyses were performed. RESULTS: We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p=0.183), or with preeclampsia with severe features (p=0.916) even after adjusting for maternal age> 35, BMI≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with development of preeclampsia (OR=13.40 95% CI [4.98-36.09]; p< 0.05), and with preeclampsia with severe features (OR=5.46 95% CI [1.65-18.02]; p< 0.05). CONCLUSIONS: We found that in an obstetric population there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia.	en_US
dc.language.iso	eng
dc.publisher	Georg Thieme Verlag KG
dc.relation.ispartofseries	American Journal of Perinatology
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	SARS-CoV-2	en_US
dc.subject	Antibody	en_US
dc.subject	Delivery	en_US
dc.subject	Risk	en_US
dc.subject	Preeclampsia	en_US
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Parto Obstétrico
dc.subject.mesh	Riesgo
dc.subject.mesh	Preeclampsia
dc.title	SARS-CoV-2 antibody status at time of delivery and the risk of preeclampsia.	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1055/a-2099-8758
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.02.03
dc.relation.issn	1098-8785